News Absolute Antibody Partners with the Recombinant Antibody Network to Facilitate Access to Engineered Recombinant Antibodies Absolute Antibody Ltd., an industry-leading provider of recombinant antibody products and services, has announced a partnership with the Recombinant Antibody Network (RAN), a consortium of three expert centers at the...
News DeepTechU Day 3: Navigating Lab to Launch, Deep Tech Investment, and a Culture Shift Toward Commercialization “The best companies we see have deep venture experience,” said Beckett Jackson, investing director, Boeing HorizonX. But they also have a grand vision about how the technology will become a...
Technology CD200-Antigen Fusion Proteins For Myeloid-Targeted Antigen-Specific Immune Tolerance CD200-antigen fusion proteins target myeloid cells to deliver inhibitory CD200R signals, enhancing antigen uptake and presentation while dampening inflammation to induce antigen-specific immune tolerance The Unmet Need: Antigen-specific therapies for…
Technology Modular Glycopolymer Technology for Antigen-Specific Immune Tolerance This technology achieves significant reduction of anti-drug antibody responses through synthetically mannosylated antigen conjugation that induces antigen-specific humoral tolerance by enhancing hepatic immune tolerance mechanisms. The Unmet Need: Effective mitigation of…
News Polsky Center Fall 2021 I-Corps Teams Tackle Unmet Medical Needs, Data Transparency, and Other Challenges The Polsky Center’s fall 2021 I-Corps cohort is developing diagnostics, novel therapeutics, innovative devices, new materials, and other technologies across various industries. The Polsky I-Corps program is a 7-week highly-experiential...
Technology Engineered Flt3L Variants For Antigen Tolerance Induction Engineered recombinant fusion of the dendritic cell growth factor Flt3L to serum albumin to modulate the antigen-presenting compartment and bias it toward tolerance particularly against therapeutic proteins. The Unmet Need:…
Technology Fully Synthetic Adjuvant Delivery System For Enhanced Tumor-Targeted Immunotherapy A cancer vaccine that enhances immune response by directly binding adjuvants to tumor cells, avoiding targeting antibodies, and reducing related side effects The problem: Therapeutic vaccination has long been a…
Technology Antibody-Polymer Conjugates For Engaging T Cells To Destroy Cancer Cells An antibody linked to a polymer that connects T cells to cancer cells enabling broad cancer targeting and effective tumor cell killing without needing tumor-specific antigens The Unmet Need: Novel…
Technology Anti-CD73(NT5E) Antibodies Specific To The Tumor Microenvironment CD73 is an ectonucleotidase tethered by a glycosylphosphatidyl anchor to the extracellular side of many cell types. Along with NTPDase-1 CD39, CD73 is an important regulator of a cells inflammatory…
Technology A Next-Generation mRNA Vaccine Platform For Enhancing T-Cell Responses And Improving Antiviral And Antitumor Immunity Next-generation mRNA vaccine platform uses a lipid-polymer hybrid nanoparticle to boost stability, immune cell uptake, and T cell responses, leading to stronger and longer-lasting protection against viruses and cancer while…
News Flu Antibodies Developed at UChicago Advance with Fast-Track Grant Antibodies developed at the University of Chicago, which target a wide variety of influenza strains, are being commercialized by Celdara Medical. The antibodies were patented by the Polsky Center for...
Technology Enhanced Vaccine Efficiency via an Antigen Targeting, Immune Stimulating Co-polymer Vaccine efficacy is limited due to the inability to deliver in-tact antigens to antigen presenting (APC) dendritic cells (DCs) while simultaneously activating the cells in a non-toxic fashion. Adjuvants have…
